Retatrutide vs Tirzepatide vs Semaglutide: How They Compare

Retatrutide, tirzepatide, and semaglutide are all once-weekly injectable drugs that drive weight loss by mimicking gut hormones, but they are not interchangeable. Tirzepatide (Zepbound) and semaglutide (Wegovy) are FDA-approved for chronic weight management in the United States, while retatrutide remains an investigational drug available only through clinical trials. In early studies, retatrutide has produced the largest average weight loss, followed by tirzepatide and then semaglutide, though no large head-to-head trial has compared all three.

What Each Drug Is and How It Works

All three medications are given as a subcutaneous injection once a week and are started at a low dose that is increased gradually to reduce gastrointestinal side effects. The key difference is how many hormone receptors each drug activates.

• Semaglutide is a GLP-1 receptor agonist. It is marketed as Wegovy for weight loss and Ozempic for type 2 diabetes, and a daily oral version (Rybelsus) is approved for diabetes.
• Tirzepatide is a dual GIP and GLP-1 receptor agonist. It is marketed as Zepbound for weight loss and Mounjaro for type 2 diabetes.
• Retatrutide is a triple agonist that targets GLP-1, GIP, and glucagon receptors. The glucagon component is thought to increase energy expenditure, and the drug is being evaluated in the Phase 3 TRIUMPH program.

Weight Loss Results Compared

Average weight loss in the major trials is roughly 15% with semaglutide 2.4 mg, about 21% with tirzepatide 15 mg, and up to 24% with retatrutide 12 mg. When people compare semaglutide vs tirzepatide weight loss, that gap of five to seven percentage points is the number most often cited.

Those figures come from separate studies with different doses, durations, and patient populations, so they are a rough guide rather than a true ranking. Individual results vary widely based on genetics, diet, activity, adherence, and how well someone tolerates dose increases.

Retatrutide's Phase 2 results were measured at 48 weeks, while the semaglutide and tirzepatide pivotal trials ran for 68 and 72 weeks. Researchers expect that retatrutide's Phase 3 data will give a clearer picture of both total weight loss and how long the effect lasts.

Side Effects and Safety

The semaglutide vs tirzepatide side effects profile is broadly similar because both drugs act on GLP-1 receptors. Most users experience at least one gastrointestinal symptom, usually in the first weeks after a dose increase.

• Common effects include nausea, vomiting, diarrhea, constipation, abdominal pain, and fatigue.
• Less common but serious risks include pancreatitis, gallbladder disease, bowel obstruction, and hypoglycemia when combined with insulin or sulfonylureas.
• Semaglutide and tirzepatide both carry a boxed warning about thyroid C-cell tumors observed in rodents and are not recommended for people with a personal or family history of medullary thyroid cancer or MEN2.
• Retatrutide's Phase 2 data showed similar gastrointestinal effects plus modest dose-related increases in heart rate and some reports of tingling or altered skin sensation, which ongoing trials are monitoring.

No GLP-1-based weight loss drug is risk-free, and all three should be used under medical supervision with regular follow-up. People who are pregnant, breastfeeding, or have a history of pancreatitis should discuss the risks with a healthcare professional before starting treatment.

Muscle Loss and Body Composition

Rapid weight loss from any cause, including these medications, can reduce lean mass along with fat. Body-composition substudies of semaglutide and tirzepatide suggest that roughly 25% to 40% of the weight lost may come from lean tissue, which is similar to what happens with diet-based weight loss of the same magnitude.

Researchers also track retatrutide muscle loss vs tirzepatide because retatrutide's glucagon activity may influence how the body uses energy and protein. There is not yet enough long-term data to say whether retatrutide preserves lean mass better or worse than tirzepatide does.

To protect muscle, clinicians generally recommend:

• Eating 1.2 to 1.6 grams of protein per kilogram of body weight per day.
• Doing resistance training two to three times per week.
• Aiming for steady weight loss rather than the fastest possible drop.

Dosing, Cost, and Access

Wegovy is escalated over about 16 to 20 weeks from 0.25 mg to 2.4 mg weekly. Zepbound starts at 2.5 mg and steps up to a maximum of 15 mg weekly over several months. Retatrutide has been studied at doses from 1 mg to 12 mg weekly but has no approved dose because it is not on the market.

List prices for brand-name Wegovy and Zepbound exceed $1,000 per month without insurance, and coverage varies widely by plan and employer. Compounded versions sold online are not FDA-approved, and regulators have warned that some compounded products may not contain the ingredients or doses their labels claim.

Which Option Makes Sense Today?

Retatrutide is not FDA-approved for human use in the United States, so it can only be obtained by joining a clinical trial. If you are asking retatrutide vs tirzepatide which is better, the practical answer is that only tirzepatide and semaglutide can be prescribed right now.

Between the two approved drugs, tirzepatide has delivered greater average weight loss in its pivotal trial, while semaglutide has a longer track record, more cardiovascular outcome data, and more formulation options. Insurance coverage, tolerability, and cost often matter more to the final choice than the trial percentages do.

The research pipeline keeps moving, and even emerging comparisons like cagrilintide vs retatrutide vs tirzepatide rely on data that has not been published yet. For now, the decision comes down to the two approved options and a conversation with a clinician.